RE: For Sure. AVACTA are going places13 Dec 2025 21:02
A cytotoxic platform that is exquisitely targetted to the site of the tumour with minimal off-target toxicity is the holy grail of chemo.
- - - - -
The "holy grail of chemotherapy" is not a specific treatment but rather a metaphorical term in cancer research that refers to an ideal, universal solution for cancer. This "holy grail" generally encompasses one or more of the following concepts:
1 - A universal cure: A single treatment or pill that is effective against all types of cancer, regardless of the tumor's origin or stage.
2 - Selective targeting: A therapy that specifically eradicates cancer cells while leaving healthy, normal cells unharmed, thus minimizing the severe side effects associated with traditional treatments like chemotherapy and radiation.
3 - Early detection: A simple, reliable test (such as a blood test or "liquid biopsy") that can accurately detect the presence of cancer at its earliest stages, often before symptoms appear, when it is most curable.
4 - Overcoming drug resistance: A strategy or treatment that can prevent cancer cells from evolving and developing resistance to therapies, which is a major challenge in long-term cancer control.
Researchers at institutions like City of Hope have developed promising molecules, such as AOH1996, that show "holy grail" potential in preclinical research by targeting a protein common to many cancers (PCNA) without harming healthy cells. Clinical trials for such innovations are ongoing, bringing the medical community closer to the dream of highly effective, less toxic cancer care.
- - - - -
1 - Good for up to 90% of solid tumours (but 100% of epithelial tumours)?
2 - This is what the pre|CISION platform does - specific for FAP
3 - Could Avacta exploit this with staining dyes rather than cytotoxins?
4 - Will be achieved with dual payloads?
Sign In
Follow the stocks
